Development of an Alcohol, Cannabis, and Sexual Assault Risk Reduction Program for High Risk College Women
21. juli 2026 oppdatert av: University of Colorado, Denver
Development of an Alcohol, Cannabis, and Sexual Assault Risk Reduction Program for High Risk College Women, Pilot RCT
The goal of this clinical trial is to assess the feasibility of the Enhanced Assess, Acknowledge, and Act Sexual Assault Resistance Program with alcohol and cannabis content (EAAA+) in undergraduate college women between ages 18-24 years old who use alcohol and cannabis. The main objectives it aims to answer are:
- To determine the feasibility of a randomized controlled trial comparing EAAA+ to an assessment only control condition.
- To determine if EAAA+ will result in larger decreases in HED and cannabis use, more accurate perceptions of alcohol and cannabis norms, and greater increases in PBS at follow up.
- To determine if EAAA+ will result in (1) greater increases in SA risk perception and use of assertive SA resistance strategies and (2) decreased barriers to SA resistance while using alcohol and cannabis, and (3) greater reductions in incapacitated SA.
Researchers will compare participants who received EAAA+ to an assessment only condition to test the objectives stated above.
Participants will:
- Sign an informed consent form and complete a survey. Once the survey is completed, they will be randomly assigned to complete the sexual assault education program or not.
- Participants assigned to the sexual assault education program will complete two in-person sessions (about 7 hours each) or four in-person sessions (about 3.5 hours each) and will also complete an online module in between modules 2 and 3 as part of the education program and complete four short surveys.
- Complete 4 weeks of assessments and complete a follow-up survey at 1, 3, and 6 months after the initial session.
Studieoversikt
Status
Har ikke rekruttert ennå
Studietype
Intervensjonell
Registrering (Antatt)
200
Fase
- Ikke aktuelt
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiekontakt
- Navn: Ruschelle M Leone, PhD
- Telefonnummer: 303-724-7052
- E-post: ruschelle.leone@cuanschutz.edu
Studiesteder
-
-
Colorado
-
Aurora, Colorado, Forente stater, 80045
- University of Colorado Anschutz Medical Campus
-
Ta kontakt med:
- Ruschelle M Leone, PhD
- Telefonnummer: 303-724-7052
- E-post: ruschelle.leone@cuanschutz.edu
-
Hovedetterforsker:
- Ruschelle M Leone, PhD
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
Tar imot friske frivillige
Ja
Beskrivelse
Inclusion Criteria:
- Provision of signed and dated informed consent form
- Stated willingness to comply with all study procedures and availability for the duration of the study determined at pre-screening
- Between the ages of 18-24 years old determined at pre-screening
- Identifies as a woman determined at pre-screening
- Is currently enrolled as an undergraduate in Colorado with a valid student email address determined at pre-screening
- Engaged in heavy episodic drinking (i.e., 4+ drinks within a two-hour period) at least once in the past month with an intention to drink in the future determined at pre-screening
- Engaged in using cannabis at least once in the past month with an intention to use in the future determined at pre-screening
- Is available to attend sessions on specific dates
- Has a phone they can complete web-based surveys on determined at pre-screening
Exclusion Criteria:
1. There are no exclusion criteria aside from not meeting inclusion criteria.
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Grunnvitenskap
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Enhanced Assess, Acknowledge, and Act Sexual Assault Resistance Program
|
Participants will be randomized to EAAA+, a combined program for alcohol and cannabis prevention and sexual assault risk reduction.
|
|
Aktiv komparator: Assessment Only Control
|
Participants will be randomized to an assessment only control.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Cannabis Use Frequency Measured at Follow-Ups
Tidsramme: Up to 1-month, 3-months, and 6-months post intervention
|
Cannabis use frequency will be reported using a self-report at 1-month and 3- and 6-month follow ups.
|
Up to 1-month, 3-months, and 6-months post intervention
|
|
Heavy Episodic Drinking Frequency Measured at Follow-Ups
Tidsramme: Up to 1-month, 3-months, and 6-months post intervention
|
Heavy episodic drinking (HED) frequency will be reported using a self-report at 1-month and 3- and 6-month follow ups.
|
Up to 1-month, 3-months, and 6-months post intervention
|
|
Attempted Sexual Assault Measured at Follow-Ups
Tidsramme: Up to 1-month, 3-months, and 6-months post intervention
|
Attempted sexual assault will be reported using a self-report at 1-month and 3- and 6-month follow ups.
|
Up to 1-month, 3-months, and 6-months post intervention
|
|
Completed Sexual Assault Measured at Follow-Ups
Tidsramme: Up to 1-month, 3-months, and 6-months post intervention
|
Completed sexual assault will be reported using a self-report at 1-month and 3- and 6-month follow ups.
|
Up to 1-month, 3-months, and 6-months post intervention
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Samarbeidspartnere
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Antatt)
1. august 2026
Primær fullføring (Antatt)
1. februar 2027
Studiet fullført (Antatt)
1. februar 2027
Datoer for studieregistrering
Først innsendt
21. juli 2026
Først innsendt som oppfylte QC-kriteriene
21. juli 2026
Først lagt ut (Faktiske)
24. juli 2026
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
24. juli 2026
Siste oppdatering sendt inn som oppfylte QC-kriteriene
21. juli 2026
Sist bekreftet
1. juli 2026
Mer informasjon
Begreper knyttet til denne studien
Andre studie-ID-numre
- 24-2079
- K01AA028844 (U.S. NIH-stipend/kontrakt)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
JA
IPD-planbeskrivelse
IPD will be available in the NIAAA Data Archive.
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .